Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
To read the full story
Related Article
- Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
- AstraZeneca Vaccine OK’ed for Age 40 and Up under Emergency Program
August 2, 2021
- Japan Approves Moderna and AstraZeneca COVID-19 Vaccines
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines in Line for Japan Approval on May 21
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
- Takeda Submits Positive Japan Data for Approval-Pending Moderna Vaccine
May 11, 2021
- Japan to Review Moderna Vaccine with Top Priority, May OK Possible: Minister
March 8, 2021
- Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
- Moderna’s COVID-19 Shot Enters Clinical Trial in Japan: Takeda
January 21, 2021
- Takeda Slated to Launch Japan PI/II for Moderna Shot in January
December 22, 2020
- Takeda Prepping for Japan Trial of Moderna COVID-19 Vaccine: MHLW Official
November 18, 2020
- Japan to Receive 50 Million Doses of Moderna COVID-19 Vaccines via Takeda
October 29, 2020
- Japan in Talks to Secure 40 Million-Plus Doses of Moderna Vaccine via Takeda: Minister
August 31, 2020
- Takeda Pairs with Novavax to Roll Out Coronavirus Vaccine in Japan, Wins 30 Billion Yen in Govt Funding
August 11, 2020
BUSINESS
- Chugai’s H1 Profit Marks 2-Digit Growth on Export to Roche Despite Lower Sales
July 26, 2024
- Takeda Will Stage Recovery at Home after 4 Drug Launches in FY2024: Japan Head
July 26, 2024
- Merck, GTRI Tie Up in Development of Parkinson’s Gene Therapy
July 26, 2024
- Intage, Niigata University Tie Up on Megalin Antagonist Development
July 26, 2024
- Global Pharma Market Grows Double Digit in 2023, Humira Stays Atop Drug Ranking: IQVIA
July 26, 2024
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…